The tweet was deleted by the author.
But we saved everything 🙂.
Greenwich LifeSciences has announced it will provide an update related to its participation in the upcoming AACR Meeting.
This move signals potential developments for the company, as industry attention focuses on presentations and clinical advancements highlighted at this major oncology event. Further details surrounding the company’s presentation are expected as the meeting date approaches.
The upcoming AACR Meeting update comes as Greenwich LifeSciences continues to build momentum following its progress in accelerating patient screening in the FLAMINGO-01 clinical trial, a development detailed in the company's earlier announcement on faster enrollment progress. These combined initiatives underscore heightened industry expectations as the company advances its oncology portfolio.